Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Purpose Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Methods Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was s...
Saved in:
Published in | European journal of clinical pharmacology Vol. 71; no. 3; pp. 341 - 355 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.03.2015
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins.
Methods
Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in
SLCO1B1
(T521>C and A388>G) and in
ABCG2
(C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed.
Results
Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51–130 %) and 55 % (26–91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25–88 %) and 69 % (37–108 %) higher for atorvastatin, 23 % (0–52 %) and 12 % (−0.9–39 %) higher for simvastatin and 28 % (5–56 %) and 34 % (10–64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in
SLCO1B1
T521>C or
ABCG2
C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the
ABCG2
C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both
SLCO1B1
and
ABCG2
, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively.
Conclusion
Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized. |
---|---|
AbstractList | Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed. Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51-130 %) and 55 % (26-91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25-88 %) and 69 % (37-108 %) higher for atorvastatin, 23 % (0-52 %) and 12 % (-0.9-39 %) higher for simvastatin and 28 % (5-56 %) and 34 % (10-64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized. Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed. Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51-130 %) and 55 % (26-91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25-88 %) and 69 % (37-108 %) higher for atorvastatin, 23 % (0-52 %) and 12 % (-0.9-39 %) higher for simvastatin and 28 % (5-56 %) and 34 % (10-64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized. Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins.PURPOSESystemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins.Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed.METHODSPlasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed.Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51-130 %) and 55 % (26-91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25-88 %) and 69 % (37-108 %) higher for atorvastatin, 23 % (0-52 %) and 12 % (-0.9-39 %) higher for simvastatin and 28 % (5-56 %) and 34 % (10-64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively.RESULTSRelative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51-130 %) and 55 % (26-91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25-88 %) and 69 % (37-108 %) higher for atorvastatin, 23 % (0-52 %) and 12 % (-0.9-39 %) higher for simvastatin and 28 % (5-56 %) and 34 % (10-64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively.Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized.CONCLUSIONIncreased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized. Purpose Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Methods Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed. Results Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51–130 %) and 55 % (26–91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25–88 %) and 69 % (37–108 %) higher for atorvastatin, 23 % (0–52 %) and 12 % (−0.9–39 %) higher for simvastatin and 28 % (5–56 %) and 34 % (10–64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2 , area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Conclusion Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized. |
Author | Bujac, Sarah R. Birmingham, Bruce K. Wei, Cheryl Azumaya, Connie T. Chen, Yusong Mosqueda-Garcia, Rogelio Elsby, Robert Ambrose, Helen J. |
Author_xml | – sequence: 1 givenname: Bruce K. surname: Birmingham fullname: Birmingham, Bruce K. email: bkbirm@comcast.net organization: AstraZeneca – sequence: 2 givenname: Sarah R. surname: Bujac fullname: Bujac, Sarah R. organization: AstraZeneca – sequence: 3 givenname: Robert surname: Elsby fullname: Elsby, Robert organization: AstraZeneca – sequence: 4 givenname: Connie T. surname: Azumaya fullname: Azumaya, Connie T. organization: AstraZeneca – sequence: 5 givenname: Cheryl surname: Wei fullname: Wei, Cheryl organization: AstraZeneca – sequence: 6 givenname: Yusong surname: Chen fullname: Chen, Yusong organization: AstraZeneca, PAREXEL International – sequence: 7 givenname: Rogelio surname: Mosqueda-Garcia fullname: Mosqueda-Garcia, Rogelio organization: AstraZeneca – sequence: 8 givenname: Helen J. surname: Ambrose fullname: Ambrose, Helen J. organization: AstraZeneca |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25673568$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1TAQhS1URG8LD8AGWWLDgsDYuc4Pm-o2KqXSlboA1pGvf6gviR08CVL7NrxpnaYFVAnkxXis74xH5xyRAx-8IeQlg3cMoHyPAJxXGbB1xipg2c0TsmLrnGcM1uyArABylhV1CYfkCHEPwEQN-TNyyEVR5qKoVuTXRT9INdJg6ea0OedUek0_b5tLdsroELrrPsThymGPNHg6XMnYSxW-O29Gp3CWxYDTT4mjHJ1_S-UY4kN3Nwtd_6dXTtNUGzkpiU4uxObuhtNub9SIH6ikqpOI1FibHk6ek6dWdmhe3Ndj8vXj2ZfmU7a9PL9oNttMCajGrM6FlEU6trag63qndZVzJi0IMIqDLXeK7ThoC1bVheZrVZdac1sAGJ6b_Ji8WeYOMfyYDI5t71CZrpPehAlbVogyZ0VV1gl9_Qjdhyn6tN1MiboQTLBEvbqnpl1vdDtE18t43T6YnwC2ACp5iNHY3wiDdg64XQJuU8DtHHB7kzTlI41ys7nBj1G67r9Kvigx_eK_mfjX0v8U3QKew7t6 |
CitedBy_id | crossref_primary_10_1007_s40262_017_0568_7 crossref_primary_10_1038_s41397_019_0122_0 crossref_primary_10_1007_s40268_024_00488_0 crossref_primary_10_1016_j_amjmed_2022_06_018 crossref_primary_10_1038_s41598_020_78231_3 crossref_primary_10_1016_j_beem_2022_101714 crossref_primary_10_12998_wjcc_v10_i5_1557 crossref_primary_10_1007_s00228_018_2420_x crossref_primary_10_3390_pharmaceutics13050709 crossref_primary_10_1016_j_jacl_2015_06_005 crossref_primary_10_1080_17425255_2019_1681399 crossref_primary_10_1111_bph_17449 crossref_primary_10_1124_dmd_115_067447 crossref_primary_10_2217_pgs_2022_0155 crossref_primary_10_1080_10408347_2018_1439364 crossref_primary_10_1038_s41572_024_00589_9 crossref_primary_10_2217_pgs_16_31 crossref_primary_10_1016_j_ijcard_2016_02_047 crossref_primary_10_1016_j_jpba_2018_07_033 crossref_primary_10_1080_17425255_2021_1876661 crossref_primary_10_3390_cimb45040228 crossref_primary_10_3390_diabetology5040031 crossref_primary_10_1007_s40265_024_02113_5 crossref_primary_10_2217_pgs_2023_0043 crossref_primary_10_38109_2225_1685_2017_1_24_31 crossref_primary_10_2147_PGPM_S482289 crossref_primary_10_1016_j_ejphar_2022_175327 crossref_primary_10_1080_03639045_2017_1414835 crossref_primary_10_2217_pgs_2021_0097 crossref_primary_10_1002_psp4_12582 crossref_primary_10_1089_omi_2016_0114 crossref_primary_10_1097_MOL_0000000000000580 crossref_primary_10_1080_17425255_2020_1801634 crossref_primary_10_1016_j_apsb_2019_01_007 crossref_primary_10_2217_pgs_2016_0065 crossref_primary_10_1007_s00228_017_2318_z crossref_primary_10_1016_j_xphs_2017_03_027 crossref_primary_10_1007_s13318_022_00798_1 crossref_primary_10_1161_ATV_0000000000000073 crossref_primary_10_1002_jcph_669 crossref_primary_10_1007_s11095_021_03109_6 crossref_primary_10_1016_j_pharmthera_2017_02_029 crossref_primary_10_1093_jac_dkz558 crossref_primary_10_1002_prp2_70073 crossref_primary_10_1111_dom_13849 crossref_primary_10_3389_fnut_2022_868126 crossref_primary_10_1007_s00228_015_1980_2 crossref_primary_10_1097_FPC_0000000000000252 crossref_primary_10_1124_dmd_118_083030 crossref_primary_10_2217_pme_2022_0041 crossref_primary_10_3389_fphar_2021_752960 crossref_primary_10_1007_s00228_021_03233_7 crossref_primary_10_1016_j_xphs_2017_05_008 crossref_primary_10_3390_ijms22062786 crossref_primary_10_1097_FPC_0000000000000260 crossref_primary_10_1002_bdd_2178 crossref_primary_10_1093_eurheartj_ehaa574 crossref_primary_10_4155_bio_2020_0242 crossref_primary_10_1097_FPC_0000000000000308 crossref_primary_10_1186_s12872_025_04611_0 crossref_primary_10_1016_j_bcp_2023_115448 crossref_primary_10_1124_dmd_118_081125 crossref_primary_10_1016_j_ajpc_2021_100157 crossref_primary_10_1124_dmd_117_078931 crossref_primary_10_1124_dmd_117_078816 crossref_primary_10_3109_00498254_2015_1130881 crossref_primary_10_2147_PGPM_S268457 crossref_primary_10_1007_s11938_022_00394_x crossref_primary_10_1016_j_semnephrol_2018_05_007 crossref_primary_10_2174_1574884714666190408125206 crossref_primary_10_1111_jcpt_12805 crossref_primary_10_2174_0115701611283841231227064343 crossref_primary_10_1002_prp2_890 crossref_primary_10_1124_dmd_115_066795 crossref_primary_10_2217_pgs_2022_0072 crossref_primary_10_2217_pgs_2016_0176 crossref_primary_10_1016_j_ejps_2022_106246 crossref_primary_10_2217_pgs_2018_0168 crossref_primary_10_1111_1755_5922_12214 crossref_primary_10_3390_jpm12121981 crossref_primary_10_1016_j_dmpk_2019_08_004 crossref_primary_10_1007_s10557_020_07070_1 crossref_primary_10_1111_bcp_13207 crossref_primary_10_1093_ehjcvp_pvab018 crossref_primary_10_3390_cells8070763 crossref_primary_10_1186_s40001_024_02109_7 crossref_primary_10_1021_acs_molpharmaceut_5b00474 crossref_primary_10_1089_omi_2023_0122 crossref_primary_10_1111_cts_13185 crossref_primary_10_1016_j_xphs_2017_04_074 crossref_primary_10_1038_s41598_020_65843_y crossref_primary_10_3390_genes15010099 crossref_primary_10_3390_ijms22073530 crossref_primary_10_2217_pme_2020_0110 crossref_primary_10_58502_DTT_24_0011 crossref_primary_10_1038_s41573_023_00877_1 crossref_primary_10_3390_ph17111411 crossref_primary_10_1136_bmjopen_2020_039034 crossref_primary_10_3389_fgene_2022_836970 crossref_primary_10_3390_pharmaceutics14030501 crossref_primary_10_1016_j_ctcp_2022_101625 crossref_primary_10_1002_cpt_3236 crossref_primary_10_1002_psp4_12837 crossref_primary_10_1016_j_clinbiochem_2024_110707 crossref_primary_10_3390_jcm9010022 crossref_primary_10_1080_17425255_2022_2132932 crossref_primary_10_1007_s00228_014_1800_0 crossref_primary_10_1002_jcph_695 crossref_primary_10_1038_s41598_018_24248_8 crossref_primary_10_3389_fgene_2020_575678 crossref_primary_10_1097_FJC_0000000000000426 crossref_primary_10_3390_jpm9030042 crossref_primary_10_1038_s41598_019_55562_4 crossref_primary_10_1111_jcpt_13299 crossref_primary_10_1097_FPC_0000000000000348 crossref_primary_10_1080_17425255_2018_1482276 crossref_primary_10_3389_fphar_2023_1102810 |
Cites_doi | 10.5551/jat.11.152 10.1016/j.clpt.2005.06.013 10.1185/03007990802312807 10.1016/j.amjcard.2007.01.028 10.1124/dmd.105.007534 10.1111/j.1365-2125.2011.03972.x 10.1038/sj.clpt.6100038 10.1038/sj.clpt.6100428 10.1074/jbc.M103792200 10.2217/pgs.13.115 10.1038/sj.clpt.6100267 10.1038/clpt.2009.79 10.1097/01.fpc.0000230416.82349.90 10.1016/j.clpt.2005.07.006 10.1185/030079907X242809 10.1007/s00228-014-1800-0 10.1038/clpt.2012.221 10.1038/sj.clpt.6100220 10.1016/S0021-9150(00)80175-6 10.1016/j.clinthera.2007.10.005 10.1016/S0149-2918(03)80316-8 10.1038/clpt.2012.163 10.1016/S0149-2918(03)80336-3 10.1097/MJT.0b013e3181f28fb5 10.1016/j.cca.2006.05.010 10.1124/dmd.108.021410 |
ContentType | Journal Article |
Copyright | Springer-Verlag Berlin Heidelberg 2015 |
Copyright_xml | – notice: Springer-Verlag Berlin Heidelberg 2015 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7U9 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 |
DOI | 10.1007/s00228-014-1801-z |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1432-1041 |
EndPage | 355 |
ExternalDocumentID | 3595226671 25673568 10_1007_s00228_014_1801_z |
Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Feature |
GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67N 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8FW 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYOK AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADOJX ADRFC ADTPH ADURQ ADYFF ADYOE ADYPR ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECT EIHBH EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 WOW Y6R YLTOR Z45 Z7U Z7V Z7W Z81 Z82 Z83 Z87 Z8O Z8P Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY 7TK 7U9 7XB 8FK H94 K9. PKEHL PQEST PQUKI 7X8 |
ID | FETCH-LOGICAL-c508t-935aa6a6af9f0d99bdd8321af050ec20f7bc1b20df0fc96d24c97dd2f600e23e3 |
IEDL.DBID | U2A |
ISSN | 0031-6970 1432-1041 |
IngestDate | Fri Jul 11 03:30:49 EDT 2025 Sat Jul 26 02:33:00 EDT 2025 Mon Jul 21 05:56:15 EDT 2025 Thu Apr 24 23:00:19 EDT 2025 Tue Jul 01 01:41:12 EDT 2025 Fri Feb 21 02:34:24 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Caucasian Pharmacogenetics Pharmacokinetics Asian |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c508t-935aa6a6af9f0d99bdd8321af050ec20f7bc1b20df0fc96d24c97dd2f600e23e3 |
Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
PMID | 25673568 |
PQID | 1655965151 |
PQPubID | 47171 |
PageCount | 15 |
ParticipantIDs | proquest_miscellaneous_1657316879 proquest_journals_1655965151 pubmed_primary_25673568 crossref_primary_10_1007_s00228_014_1801_z crossref_citationtrail_10_1007_s00228_014_1801_z springer_journals_10_1007_s00228_014_1801_z |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-03-01 |
PublicationDateYYYYMMDD | 2015-03-01 |
PublicationDate_xml | – month: 03 year: 2015 text: 2015-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
PublicationTitle | European journal of clinical pharmacology |
PublicationTitleAbbrev | Eur J Clin Pharmacol |
PublicationTitleAlternate | Eur J Clin Pharmacol |
PublicationYear | 2015 |
Publisher | Springer Berlin Heidelberg Springer Nature B.V |
Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
References | TironaRGLeakeBFMerinoGKimRBPolymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-AmericansJ Biol Chem2001276356693567510.1074/jbc.M1037922001:CAS:528:DC%2BD3MXntFahsb4%3D11477075 LeeHKHuMLuiSSHoCSWongCKTomlinsonBEffects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patientsPharmacogenomics2013141283129410.2217/pgs.13.1151:CAS:528:DC%2BC3sXht1Chtb7M23930675 TzengTBSchneckDWBirminghamBKMitchellPDZhangHMartinPDKungLPPopulation pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemiaCurr Med Res Opin2008242575258510.1185/030079908023128071:CAS:528:DC%2BD1cXhtlKit7rK18674408 Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99–103 KeskitaloJEZolkOFrommMFKurkinenKJNeuvonenPJNiemiMABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatinClin Pharmacol Ther20098619720310.1038/clpt.2009.791:CAS:528:DC%2BD1MXovFOrtrg%3D19474787 AllredAJBowenCJParkJWPengBWilliamsDDWireMBLeeEEltrombopag increases plasma rosuvastatin exposure in healthy volunteersBr J Clin Pharmacol20117232132910.1111/j.1365-2125.2011.03972.x31626611:CAS:528:DC%2BC3MXhtV2qtrvE21434975 MartinPDWarwickMJDaneALBrindleyCShortTAbsolute oral bioavailability of rosuvastatin in healthy white adult male volunteersClin Ther2003252553256310.1016/S0149-2918(03)80316-81:CAS:528:DC%2BD3sXpvVGksLk%3D14667956 PasanenMKNeuvonenMNeuvonenPJNiemiMSLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenet Genomics20061687387910.1097/01.fpc.0000230416.82349.901:CAS:528:DC%2BD28Xht1SmtrvP17108811 PasanenMKFredriksonHNeuvonenPJNiemiMDifferent effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatinClin Pharmacol Ther20078272673310.1038/sj.clpt.61002201:CAS:528:DC%2BD2sXht1ymu7jM17473846 ChoiJHLeeMGChoJYLeeJEKimKHParkKInfluence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in KoreansClin Pharmacol Ther20088325125710.1038/sj.clpt.61002671:CAS:528:DC%2BD1cXitFKjtLY%3D17568401 LauYYHuangYFrassettoLBenetLZEffect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteersClin Pharmacol Ther20078119420410.1038/sj.clpt.61000381:CAS:528:DC%2BD2sXisFyrtLY%3D17192770 ZhuJRTomlinsonBRoYMSimKHLeeYTSriratanasathavornCA randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)Curr Med Res Opin2007233055306810.1185/030079907X2428091:CAS:528:DC%2BD1cXhslOksLc%3D18196620 MartinPDWarwickMJDaneALHillSJGilesPBPhillipsPJLenzEMetabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteersClin Ther2003252822283510.1016/S0149-2918(03)80336-31:CAS:528:DC%2BD2cXhtVynsQ%3D%3D14693307 WarwickMJDaneALRazaASchneckDWSingle- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522Atherosclerosis20001513910.1016/S0021-9150(00)80175-6(Abstract) LeeERyanSBirminghamBZalikowskiJMarchRAmbroseHMooreRLeeCChenYSchneckDRosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environmentClin Pharmacol Ther20057833034110.1016/j.clpt.2005.06.0131:CAS:528:DC%2BD2MXhtVGrsLfF16198652 Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, Kim K, Ambrose HJ (2015) Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol doi: 10.1007/s00228-014-1800-0 Tomita Y, Maeda K, Sugiyama Y (2013) Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther 94:37–51 Gandelman K, Fung GL, Messig M, Laskey R (2012) Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am J Ther 19:164–173 Mabuchi H, Nohara A, Higashikata T, Ueda K, Bujo H, Matsushima T, Ikeda Y, Nii M (2004) Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 11:152–158 KitamuraSMaedaKWangYSugiyamaYInvolvement of multiple transporters in the hepatobiliary transport of rosuvastatinDrug Metab Dispos2008362014202310.1124/dmd.108.0214101:CAS:528:DC%2BD1cXhtF2jtLbJ18617601 TironaRGEthnic differences in statin dispositionClin Pharmacol Ther20057831131610.1016/j.clpt.2005.07.0061:CAS:528:DC%2BD2MXhtVGrsLfK16198649 DeedwaniaPCGuptaMSteinMYcasJGoldAIRIS Study GroupComparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial)Am J Cardiol2007991538154310.1016/j.amjcard.2007.01.0281:CAS:528:DC%2BD2sXlvVaktLk%3D17531577 ElsbyRHilgendorfCFennerKUnderstanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1Clin Pharmacol Ther20129258459810.1038/clpt.2012.1631:CAS:528:DC%2BC38XhsFChsbjL23047648 LiYJiangXLanKZhangRLiXJiangQPharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover studyClin Ther2007292194220310.1016/j.clinthera.2007.10.0051:CAS:528:DC%2BD2sXhsVygtrfJ18042475 HuangLWangYGrimmSATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance proteinDrug Metab Dispos20063473874210.1124/dmd.105.0075341:CAS:528:DC%2BD28Xks1Sks7c%3D16415124 KimKBirminghamBKAzumayaCTZalikowskiJChenYSchneckDIncreased systemic exposure to rosuvastatin in Asian subjects residing in the United States compared with Caucasian subjectsClin Pharmacol Ther200883S1410.1038/sj.clpt.6100428(Abstract) K Kim (1801_CR7) 2008; 83 JH Choi (1801_CR11) 2008; 83 E Lee (1801_CR2) 2005; 78 PD Martin (1801_CR9) 2003; 25 AJ Allred (1801_CR25) 2011; 72 PC Deedwania (1801_CR3) 2007; 99 L Huang (1801_CR14) 2006; 34 MJ Warwick (1801_CR5) 2000; 151 1801_CR26 RG Tirona (1801_CR17) 2005; 78 1801_CR20 S Kitamura (1801_CR12) 2008; 36 RG Tirona (1801_CR13) 2001; 276 JR Zhu (1801_CR4) 2007; 23 MK Pasanen (1801_CR22) 2007; 82 PD Martin (1801_CR10) 2003; 25 TB Tzeng (1801_CR8) 2008; 24 HK Lee (1801_CR21) 2013; 14 R Elsby (1801_CR18) 2012; 92 Y Li (1801_CR6) 2007; 29 1801_CR19 MK Pasanen (1801_CR24) 2006; 16 YY Lau (1801_CR23) 2007; 81 1801_CR16 1801_CR1 JE Keskitalo (1801_CR15) 2009; 86 23047648 - Clin Pharmacol Ther. 2012 Nov;92 (5):584-98 25630984 - Eur J Clin Pharmacol. 2015 Mar;71(3):329-40 14693307 - Clin Ther. 2003 Nov;25(11):2822-35 14667956 - Clin Ther. 2003 Oct;25(10):2553-63 19474787 - Clin Pharmacol Ther. 2009 Aug;86(2):197-203 17108811 - Pharmacogenet Genomics. 2006 Dec;16(12 ):873-9 20975528 - Am J Ther. 2012 May;19(3):164-73 18196620 - Curr Med Res Opin. 2007 Dec;23(12):3055-68 11477075 - J Biol Chem. 2001 Sep 21;276(38):35669-75 18674408 - Curr Med Res Opin. 2008 Sep;24(9):2575-85 17568401 - Clin Pharmacol Ther. 2008 Feb;83(2):251-7 15256766 - J Atheroscler Thromb. 2004;11(3):152-8 16415124 - Drug Metab Dispos. 2006 May;34(5):738-42 17473846 - Clin Pharmacol Ther. 2007 Dec;82(6):726-33 23930675 - Pharmacogenomics. 2013 Aug;14 (11):1283-94 18617601 - Drug Metab Dispos. 2008 Oct;36(10 ):2014-23 16784736 - Clin Chim Acta. 2006 Nov;373(1-2):99-103 16198649 - Clin Pharmacol Ther. 2005 Oct;78(4):311-6 16198652 - Clin Pharmacol Ther. 2005 Oct;78(4):330-41 17531577 - Am J Cardiol. 2007 Jun 1;99(11):1538-43 17192770 - Clin Pharmacol Ther. 2007 Feb;81(2):194-204 23443754 - Clin Pharmacol Ther. 2013 Jul;94(1):37-51 21434975 - Br J Clin Pharmacol. 2011 Aug;72 (2):321-9 18042475 - Clin Ther. 2007 Oct;29(10):2194-203 |
References_xml | – reference: KeskitaloJEZolkOFrommMFKurkinenKJNeuvonenPJNiemiMABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatinClin Pharmacol Ther20098619720310.1038/clpt.2009.791:CAS:528:DC%2BD1MXovFOrtrg%3D19474787 – reference: TzengTBSchneckDWBirminghamBKMitchellPDZhangHMartinPDKungLPPopulation pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemiaCurr Med Res Opin2008242575258510.1185/030079908023128071:CAS:528:DC%2BD1cXhtlKit7rK18674408 – reference: TironaRGEthnic differences in statin dispositionClin Pharmacol Ther20057831131610.1016/j.clpt.2005.07.0061:CAS:528:DC%2BD2MXhtVGrsLfK16198649 – reference: LauYYHuangYFrassettoLBenetLZEffect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteersClin Pharmacol Ther20078119420410.1038/sj.clpt.61000381:CAS:528:DC%2BD2sXisFyrtLY%3D17192770 – reference: LeeHKHuMLuiSSHoCSWongCKTomlinsonBEffects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patientsPharmacogenomics2013141283129410.2217/pgs.13.1151:CAS:528:DC%2BC3sXht1Chtb7M23930675 – reference: Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, Kim K, Ambrose HJ (2015) Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol doi: 10.1007/s00228-014-1800-0 – reference: Mabuchi H, Nohara A, Higashikata T, Ueda K, Bujo H, Matsushima T, Ikeda Y, Nii M (2004) Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 11:152–158 – reference: PasanenMKNeuvonenMNeuvonenPJNiemiMSLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenet Genomics20061687387910.1097/01.fpc.0000230416.82349.901:CAS:528:DC%2BD28Xht1SmtrvP17108811 – reference: HuangLWangYGrimmSATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance proteinDrug Metab Dispos20063473874210.1124/dmd.105.0075341:CAS:528:DC%2BD28Xks1Sks7c%3D16415124 – reference: LeeERyanSBirminghamBZalikowskiJMarchRAmbroseHMooreRLeeCChenYSchneckDRosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environmentClin Pharmacol Ther20057833034110.1016/j.clpt.2005.06.0131:CAS:528:DC%2BD2MXhtVGrsLfF16198652 – reference: KimKBirminghamBKAzumayaCTZalikowskiJChenYSchneckDIncreased systemic exposure to rosuvastatin in Asian subjects residing in the United States compared with Caucasian subjectsClin Pharmacol Ther200883S1410.1038/sj.clpt.6100428(Abstract) – reference: MartinPDWarwickMJDaneALHillSJGilesPBPhillipsPJLenzEMetabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteersClin Ther2003252822283510.1016/S0149-2918(03)80336-31:CAS:528:DC%2BD2cXhtVynsQ%3D%3D14693307 – reference: Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99–103 – reference: ZhuJRTomlinsonBRoYMSimKHLeeYTSriratanasathavornCA randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)Curr Med Res Opin2007233055306810.1185/030079907X2428091:CAS:528:DC%2BD1cXhslOksLc%3D18196620 – reference: PasanenMKFredriksonHNeuvonenPJNiemiMDifferent effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatinClin Pharmacol Ther20078272673310.1038/sj.clpt.61002201:CAS:528:DC%2BD2sXht1ymu7jM17473846 – reference: LiYJiangXLanKZhangRLiXJiangQPharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover studyClin Ther2007292194220310.1016/j.clinthera.2007.10.0051:CAS:528:DC%2BD2sXhsVygtrfJ18042475 – reference: ElsbyRHilgendorfCFennerKUnderstanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1Clin Pharmacol Ther20129258459810.1038/clpt.2012.1631:CAS:528:DC%2BC38XhsFChsbjL23047648 – reference: KitamuraSMaedaKWangYSugiyamaYInvolvement of multiple transporters in the hepatobiliary transport of rosuvastatinDrug Metab Dispos2008362014202310.1124/dmd.108.0214101:CAS:528:DC%2BD1cXhtF2jtLbJ18617601 – reference: TironaRGLeakeBFMerinoGKimRBPolymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-AmericansJ Biol Chem2001276356693567510.1074/jbc.M1037922001:CAS:528:DC%2BD3MXntFahsb4%3D11477075 – reference: ChoiJHLeeMGChoJYLeeJEKimKHParkKInfluence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in KoreansClin Pharmacol Ther20088325125710.1038/sj.clpt.61002671:CAS:528:DC%2BD1cXitFKjtLY%3D17568401 – reference: Gandelman K, Fung GL, Messig M, Laskey R (2012) Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am J Ther 19:164–173 – reference: DeedwaniaPCGuptaMSteinMYcasJGoldAIRIS Study GroupComparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial)Am J Cardiol2007991538154310.1016/j.amjcard.2007.01.0281:CAS:528:DC%2BD2sXlvVaktLk%3D17531577 – reference: AllredAJBowenCJParkJWPengBWilliamsDDWireMBLeeEEltrombopag increases plasma rosuvastatin exposure in healthy volunteersBr J Clin Pharmacol20117232132910.1111/j.1365-2125.2011.03972.x31626611:CAS:528:DC%2BC3MXhtV2qtrvE21434975 – reference: MartinPDWarwickMJDaneALBrindleyCShortTAbsolute oral bioavailability of rosuvastatin in healthy white adult male volunteersClin Ther2003252553256310.1016/S0149-2918(03)80316-81:CAS:528:DC%2BD3sXpvVGksLk%3D14667956 – reference: Tomita Y, Maeda K, Sugiyama Y (2013) Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther 94:37–51 – reference: WarwickMJDaneALRazaASchneckDWSingle- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522Atherosclerosis20001513910.1016/S0021-9150(00)80175-6(Abstract) – ident: 1801_CR1 doi: 10.5551/jat.11.152 – volume: 78 start-page: 330 year: 2005 ident: 1801_CR2 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.06.013 – volume: 24 start-page: 2575 year: 2008 ident: 1801_CR8 publication-title: Curr Med Res Opin doi: 10.1185/03007990802312807 – volume: 99 start-page: 1538 year: 2007 ident: 1801_CR3 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2007.01.028 – volume: 34 start-page: 738 year: 2006 ident: 1801_CR14 publication-title: Drug Metab Dispos doi: 10.1124/dmd.105.007534 – volume: 72 start-page: 321 year: 2011 ident: 1801_CR25 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2011.03972.x – volume: 81 start-page: 194 year: 2007 ident: 1801_CR23 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100038 – volume: 83 start-page: S14 year: 2008 ident: 1801_CR7 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100428 – volume: 276 start-page: 35669 year: 2001 ident: 1801_CR13 publication-title: J Biol Chem doi: 10.1074/jbc.M103792200 – volume: 14 start-page: 1283 year: 2013 ident: 1801_CR21 publication-title: Pharmacogenomics doi: 10.2217/pgs.13.115 – volume: 83 start-page: 251 year: 2008 ident: 1801_CR11 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100267 – volume: 86 start-page: 197 year: 2009 ident: 1801_CR15 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2009.79 – volume: 16 start-page: 873 year: 2006 ident: 1801_CR24 publication-title: Pharmacogenet Genomics doi: 10.1097/01.fpc.0000230416.82349.90 – volume: 78 start-page: 311 year: 2005 ident: 1801_CR17 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.07.006 – volume: 23 start-page: 3055 year: 2007 ident: 1801_CR4 publication-title: Curr Med Res Opin doi: 10.1185/030079907X242809 – ident: 1801_CR16 doi: 10.1007/s00228-014-1800-0 – ident: 1801_CR26 doi: 10.1038/clpt.2012.221 – volume: 82 start-page: 726 year: 2007 ident: 1801_CR22 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100220 – volume: 151 start-page: 39 year: 2000 ident: 1801_CR5 publication-title: Atherosclerosis doi: 10.1016/S0021-9150(00)80175-6 – volume: 29 start-page: 2194 year: 2007 ident: 1801_CR6 publication-title: Clin Ther doi: 10.1016/j.clinthera.2007.10.005 – volume: 25 start-page: 2553 year: 2003 ident: 1801_CR9 publication-title: Clin Ther doi: 10.1016/S0149-2918(03)80316-8 – volume: 92 start-page: 584 year: 2012 ident: 1801_CR18 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2012.163 – volume: 25 start-page: 2822 year: 2003 ident: 1801_CR10 publication-title: Clin Ther doi: 10.1016/S0149-2918(03)80336-3 – ident: 1801_CR19 doi: 10.1097/MJT.0b013e3181f28fb5 – ident: 1801_CR20 doi: 10.1016/j.cca.2006.05.010 – volume: 36 start-page: 2014 year: 2008 ident: 1801_CR12 publication-title: Drug Metab Dispos doi: 10.1124/dmd.108.021410 – reference: 16415124 - Drug Metab Dispos. 2006 May;34(5):738-42 – reference: 11477075 - J Biol Chem. 2001 Sep 21;276(38):35669-75 – reference: 16784736 - Clin Chim Acta. 2006 Nov;373(1-2):99-103 – reference: 17568401 - Clin Pharmacol Ther. 2008 Feb;83(2):251-7 – reference: 17531577 - Am J Cardiol. 2007 Jun 1;99(11):1538-43 – reference: 20975528 - Am J Ther. 2012 May;19(3):164-73 – reference: 18674408 - Curr Med Res Opin. 2008 Sep;24(9):2575-85 – reference: 15256766 - J Atheroscler Thromb. 2004;11(3):152-8 – reference: 23047648 - Clin Pharmacol Ther. 2012 Nov;92 (5):584-98 – reference: 21434975 - Br J Clin Pharmacol. 2011 Aug;72 (2):321-9 – reference: 23930675 - Pharmacogenomics. 2013 Aug;14 (11):1283-94 – reference: 16198649 - Clin Pharmacol Ther. 2005 Oct;78(4):311-6 – reference: 14693307 - Clin Ther. 2003 Nov;25(11):2822-35 – reference: 19474787 - Clin Pharmacol Ther. 2009 Aug;86(2):197-203 – reference: 17473846 - Clin Pharmacol Ther. 2007 Dec;82(6):726-33 – reference: 16198652 - Clin Pharmacol Ther. 2005 Oct;78(4):330-41 – reference: 17108811 - Pharmacogenet Genomics. 2006 Dec;16(12 ):873-9 – reference: 18196620 - Curr Med Res Opin. 2007 Dec;23(12):3055-68 – reference: 14667956 - Clin Ther. 2003 Oct;25(10):2553-63 – reference: 17192770 - Clin Pharmacol Ther. 2007 Feb;81(2):194-204 – reference: 23443754 - Clin Pharmacol Ther. 2013 Jul;94(1):37-51 – reference: 18042475 - Clin Ther. 2007 Oct;29(10):2194-203 – reference: 18617601 - Drug Metab Dispos. 2008 Oct;36(10 ):2014-23 – reference: 25630984 - Eur J Clin Pharmacol. 2015 Mar;71(3):329-40 |
SSID | ssj0015903 |
Score | 2.4641387 |
Snippet | Purpose
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased... Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 341 |
SubjectTerms | Adolescent Adult Aged Asian Continental Ancestry Group - genetics Asian people Atorvastatin Calcium - adverse effects Atorvastatin Calcium - blood Atorvastatin Calcium - pharmacokinetics ATP Binding Cassette Transporter, Sub-Family G, Member 2 ATP-Binding Cassette Transporters - genetics Biomedical and Life Sciences Biomedicine European Continental Ancestry Group - genetics Female Genotype Genotype & phenotype Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics Male Middle Aged Neoplasm Proteins - genetics Organic Anion Transporters - genetics Pharmacokinetics and Disposition Pharmacology Pharmacology/Toxicology Polymorphism Polymorphism, Single Nucleotide - genetics Rosuvastatin Calcium - adverse effects Rosuvastatin Calcium - blood Rosuvastatin Calcium - pharmacokinetics Simvastatin - adverse effects Simvastatin - analogs & derivatives Simvastatin - blood Simvastatin - pharmacokinetics Solute Carrier Organic Anion Transporter Family Member 1b1 Statins White people Young Adult |
SummonAdditionalLinks | – databaseName: ProQuest Health & Medical Collection (NC LIVE) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgvPCCGNfAQEZCe4Ba2ImT1LxMXcUYiMskNqlvkeOLVG1NytIidf-Gf8o5zqWgiSkPSRTbsXJOfD7fvo-Q12WSQdg1no0hHjCk0GLaopq7ks4K6zi3uBv567fs-Ex-nqWzbsCt6ZZV9m1iaKhtbXCM_J3IAPuibrc4WP5kqBqFs6udhMZtcgepy9Cr89nQ4YJIzTvSXcEylQ-zmjyQiMbIzSwkE9BIs6t_49I1sHltojTEn6P75F4HHOmktfQuueWqB2T_pGWe3ozo6XYjVTOi-_Rky0m9eUh-fwq7IWnt6eRw-jGmurL0x5fpd3Eo6LK-2Cxq-ODzZtHQuqLLLu85QFAsD7NBrde_NO4_mlcjil31_i6U1cwX23sztxTOU42KauB_IcUkXDXrEkd-mvdUU4PInbYrSg4ekbOjD6fTY9apMzADoG7FVJJqncHhledWqdJaVD3SnqfcmZj7vDSijLn13BuV2VgalVsbe4BYLk5c8pjsVHXlnhIqpbdClgBGx6WUGsKHcmkis7ETmdZGR4T3tilMR12OChoXxUC6HMxZgDkLNGdxFZE3Q5Zly9txU-K93uBF9ws3xdbhIvJqeAw_H86o6MrV65AmKH_lKiJPWkcZ3gZYMk_SbByRt73n_FX4_6ry7OaqPCd3AbGl7SK4PbKzuly7F4CKVuXL4Pp_AO34Ci8 priority: 102 providerName: ProQuest |
Title | Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? |
URI | https://link.springer.com/article/10.1007/s00228-014-1801-z https://www.ncbi.nlm.nih.gov/pubmed/25673568 https://www.proquest.com/docview/1655965151 https://www.proquest.com/docview/1657316879 |
Volume | 71 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfY9sILYnwGRmUktAdoJDtxkpoXlFTtxlepYJXKU-T4Q6rYkmppkbb_hv-Us_NR0AAJ5cGxYl-snO37Xc53h9CLIoxB7Erjj0Ae-DaEli-UzebOmVZUaUKU9Ub-OItPF-zdMlq2ftx1d9q9M0m6nbp3dnOhWkD1ZT6FbdW_3kMHEaju9hzXIkh700HESRtpl_oxT3pT5p9I_C6MbiDMG9ZRJ3Smd9GdFi3itGHvIbqly3voeN6Em74a4rOd91Q9xMd4vgtEfXUf_XjrXCBxZXCajU8CLEqFv3wYf6IZxevqHNR--Mqr-qLGVYnXbd9vgDstPdsNRr39LqzT0aocYqufdzVHq15d7OpypTCUY2HTqMGkcy1Sd1dvC_u7p36NBZYWruPmGMmbB2gxnZyNT_02JYMvAcltfB5GQsRwGW6I4rxQyqY6EoZERMuAmKSQtAiIMsRIHquASZ4oFRjAVToIdfgQ7ZdVqR8jzJhRlBWAQEcFYwJkBtdRyOKRprEQUniIdLzJZRuv3KbNOM_7SMuOnTmwM7fszK899LLvsm6Cdfyr8VHH8Lxdt3VOY9CwbHZ46qHn_WNYcdaMIkpdbV0bl-4r4R561EyU_m0AIJMwikceetXNnF-I_20oT_6r9VN0G1Bb1ByEO0L7m8utfgbIaFMM0F6yTAboIJ1m2cyWJ1_fT6DMJrP554FbJz8B4r4MsQ |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGeIAXxJ2MAUaCPUAj7MRJGiQ0dYXRsm5MopP6FhzbkaqtSSEtqPs3_AF-I-c4l4Im9jb1oY1qO5bOsc_ny_k-Ql6kfghhV2VuF-KBixRartSo5h4Lo7k2jGnMRj48Cgcn4tMkmGyQ300uDF6rbOZEO1HrQuEe-RseAvZF3W6-O__momoUnq42EhqVWxyY1U9YspXvhu_Bvi89b__DuD9wa1UBVwEYWbixH0gZwieLM6bjONUa1XpkxgJmlMeyKFU89ZjOWKbiUHtCxZHWXgbQwHi-8aHda-Q6BF6Gi71o0i7wABmwmuSXu2EctaeozJKWesgFzYXLISi45__GwQvg9sLBrI13-7fJrRqo0l7lWXfIhsnvkp3jiul61aHjdeJW2aE79HjNgb26R34NbfYlLTLa2-t_9KjMNf0y6n_me5zOi7PVrAADT8tZSYuczuu6pwB5sT2sBr1e_pCY7zTNOxS3Bpon21Y5na2f1VRT-O5LVHADf7clevZXuUxxp6l8SyVVuFKg1Q2W3fvk5Ers9oBs5kVuHhEqRKa5SAH8dlMhJISr2AS-CLuGh1Iq6RDW2CZRNVU6KnacJS3JszVnAuZM0JzJuUNetVXmFU_IZYW3G4Mn9ZRRJmsHd8jz9m8Y7HiCI3NTLG0ZqzQWxQ55WDlK-zbArpEfhF2HvG4856_G_9eVrcu78ozcGIwPR8loeHTwmNwEtBhUF_C2yebi-9I8AUS2SJ_aYUDJ16sed38AXrdIkA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJyFeEHcKA4wEe4BGs3OtkdDUdisrG6WCTdpbcHyRKtakkBbU_Rv-Br-Oc3IraGJvUx6SKLZj6Rz7fPbx-Q4hLxIvBLOrrNMFe-AghZYjNWZzF77RXBvGNEYjfxiHByf--9PgdIP8rmNh8FhlPScWE7XOFO6R7_AQsC_m7eY7tjoWMdkb7s6_OZhBCj2tdTqNUkUOzeonLN_yt6M9kPVL1x3uHw8OnCrDgKMAmCwc4QVShnBZYZkWItEaM_dIywJmlMtslCieuExbZpUItesrEWntWoAJxvWMB-1eI5sRropaZLO_P558anwYgWAV5S93QhE1PlVWUJi6yAzNfYeDiXDO_7WKF6DuBTdtYf2Gt8jNCrbSXqlnt8mGSe-Q7UnJe73q0ON1GFfeodt0smbEXt0lv0ZFLCbNLO31B-9cKlNNPx8NPvI-p_PsbDXLQNzTfJbTLKXzqu5XAMDYHlaDXi9_SIx-mqYdihsF9VvRVj6drd_VVFO4DyTmcwPtL0r0iqd8meC-U_6GSqpw3UDL8yy798jJlUjuPmmlWWoeEur7VnM_ASjcTXxfgvESJvD8sGt4KKWSbcJq2cSqIk7H_B1ncUP5XIgzBnHGKM74vE1eNVXmJWvIZYW3aoHH1QSSx2t1b5PnzWcY-ujPkanJlkWZIu9YJNrkQakozd8AyUZeEHbb5HWtOX81_r-uPLq8K8_IdRhz8dFofPiY3ADoGJSn8bZIa_F9aZ4APFskT6txQMmXqx56fwA_P04r |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+ABCG2+and+SLCO1B1+polymorphisms+on+pharmacokinetics+of+rosuvastatin%2C+atorvastatin+and+simvastatin+acid+in+Caucasian+and+Asian+subjects%3A+a+class+effect%3F&rft.jtitle=European+journal+of+clinical+pharmacology&rft.au=Birmingham%2C+Bruce+K&rft.au=Bujac%2C+Sarah+R&rft.au=Elsby%2C+Robert&rft.au=Azumaya%2C+Connie+T&rft.date=2015-03-01&rft.issn=1432-1041&rft.eissn=1432-1041&rft.volume=71&rft.issue=3&rft.spage=341&rft_id=info:doi/10.1007%2Fs00228-014-1801-z&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6970&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6970&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6970&client=summon |